Challenges and opportunities of combining RWE and RCT data
I've been working on RWE most of my career and the clinical trial data for a while now. And 20 years ago, we would have never thought about merging them together but there's a lot of opportunities if we do this.
The recent advances in analytical methods for combining evidence from RCTs and non-RCTs, and the development of new frameworks for the inclusion of RWE in HTA have provided a greater insight on how issues around RWE uncertainty can be dealt with when estimating treatment effects for new technologies.